Delisting riskPopularity #4,333
Lakeside (QNME)
Distributes infusion, specialty-prescription, and medical-nutrition products through China's healthcare channels.
$1.04
vs last close+0.40 (+62.60%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Jun 2023 | Q1 FY24Sep 2023 | Q2 FY24Dec 2023 | Q3 FY24Mar 2024 | Q4 FY24Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 4 | 6 | 6 | 7 | 1 |
| Cost of revenue | 3 | 4 | 5 | 4 | 4 | 4 | 4 | 3 | 5 | 5 | 5 | 0 |
| Gross profit | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 1 |
| 1 | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | |
| 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| General & administrative | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other expenses | 1 | 0 | −1 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | 1 | −1 | −2 | −1 | −1 | −1 | −1 | −2 |
| 1 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 1 | 0 | 0 | 0 | 0 | −1 | −2 | −1 | −1 | −1 | −2 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 0 | −1 | −2 | −1 | −1 | −1 | −2 | −2 |
| Net income | 0 | 0 | 0 | 0 | 0 | −1 | −2 | −1 | −1 | −1 | −2 | −2 |
| EPS, basic | $0.05 | −$0.04 | $0.01 | $0.00 | $0.00 | −$0.18 | −$0.26 | −$0.14 | −$0.11 | −$0.09 | −$0.08 | −$0.04 |
| EPS, diluted | $0.07 | −$0.04 | $0.01 | $0.00 | $0.00 | −$0.18 | −$0.26 | −$0.14 | −$0.11 | −$0.09 | −$0.08 | −$0.04 |
| Weighted average shares, basic | 8 | 8 | 8 | 8 | 7 | 8 | 8 | 8 | 8 | 8 | 20 | 34 |
| Weighted average shares, diluted | 8 | 8 | 8 | 8 | 7 | 8 | 8 | 8 | 8 | 8 | 20 | 34 |
| EBITDA | 1 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | 0 | −1 | −1 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 1 | 0 | 0 | 0 | 0 | −1 | −2 | −1 | 0 | −1 | −1 | −1 |